DAWN

Day One Biopharmaceuticals, Inc. Common Stock

$21.53 +0.19%

Recent alerts on DAWN

All signals →

News Day One (DAWN) In-Licenses MabCare Cancer Candidate, Stock Up

News Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio

News Day One Biopharma to be acquired by Servier for $2.5B

Scanner Unusual buy pressure (4.4x avg, 61% up-volume, +27.7% / +2.81 intraday, above VWAP)

SEC filing DAWN Reports $441M Cash, OJEMDA Approval, Mersana Deal, 2026 Growth Plans

Insider trade Sale by Adam Dubow

Insider trade Sale by Michael Vasconcelles

Insider trade Sale by Charles N York II

Short volume Short volume 75% of volume (4.9σ)

News Day One projects 2026 OJEMDA U.S. net product revenue between $225M - $250M

News Day One Completes Acquisition of Mersana Therapeutics

News BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alexander & Baldwin, Inc. (NYSE - ALEX), United Security Bancshares (Nasdaq - UBFO), Udemy, Inc. (Nasdaq - UDMY), Mersana Therapeutics, Inc. (Nasdaq - MRSN)

News Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout

Get push alerts for DAWN

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS